Clinical outcome and safety of rituximab therapy for pemphigoid diseases
Description of this data
Supplemental materials for this retrospective case series including all (n=38) pemphigoid patients at the University of Pennsylvania followed at least 1 year after RTX or until death. Outcomes followed consensus definitions. The primary endpoint was complete remission (CR). Secondary endpoints were CR off therapy (CROT), corticosteroid dose, relapse, serious adverse events (SAEs), and autoantibody titers.
Experiment data files
Cite this dataset
Tovanabutra, Napatra; Payne, Aimee S (2020), “Clinical outcome and safety of rituximab therapy for pemphigoid diseases”, Mendeley Data, v1 http://dx.doi.org/10.17632/7j5vv3rryc.1
The files associated with this dataset are licensed under a Creative Commons Attribution 4.0 International licence.